{"id":"rocklatan-0-02-0-005-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hyperemia"},{"rate":"10-20","effect":"Eye irritation"},{"rate":"5-15","effect":"Corneal verticillata"},{"rate":"5-10","effect":"Increased iris pigmentation"},{"rate":"5-10","effect":"Eyelash growth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Netarsudil, the rho kinase inhibitor component, increases conventional and uveoscleral outflow of aqueous humor and reduces aqueous humor production. Latanoprost, the prostaglandin F analog, further increases uveoscleral outflow. Together, these dual mechanisms provide additive intraocular pressure reduction in glaucoma and ocular hypertension patients.","oneSentence":"Rocklatan combines a prostaglandin analog and a rho kinase inhibitor to reduce intraocular pressure through increased uveoscleral outflow and decreased aqueous humor production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:19.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07325240","phase":"PHASE4","title":"24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-21","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT06819046","phase":"","title":"Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment","status":"COMPLETED","sponsor":"Colorado Ophthalmology Associates PC","startDate":"2025-02-14","conditions":"Glaucoma","enrollment":70},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT07082816","phase":"PHASE3","title":"Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alcon Research","startDate":"2025-09-02","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":489},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT05283395","phase":"PHASE4","title":"Rocklatan® Evaluation","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-03-28","conditions":"Glaucoma","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rocklatan 0.02%-0.005% Ophthalmic Solution","genericName":"Rocklatan 0.02%-0.005% Ophthalmic Solution","companyName":"Eye Centers of Southeast Texas","companyId":"eye-centers-of-southeast-texas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rocklatan combines a prostaglandin analog and a rho kinase inhibitor to reduce intraocular pressure through increased uveoscleral outflow and decreased aqueous humor production. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}